These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 9076381)

  • 1. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
    Grip L; Blombäck M; Egberg N; Olsson A; Svane B; Velander M
    Eur Heart J; 1997 Mar; 18(3):443-9. PubMed ID: 9076381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial.
    Schächinger V; Allert M; Kasper W; Just H; Vach W; Zeiher AM
    Circulation; 1994 Nov; 90(5):2258-66. PubMed ID: 7955182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters.
    Suzuki S; Matsuo T; Kobayashi H; Matsuo M; Shimamo C; Koide M; Sakamoto S
    Thromb Res; 2000 May; 98(4):269-79. PubMed ID: 10822073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive infusion of antithrombin III during percutaneous transluminal coronary angioplasty.
    Huber K; Maurer G
    Eur Heart J; 1997 Mar; 18(3):362-3. PubMed ID: 9076371
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
    Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
    J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
    Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
    J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris.
    Laskey MA; Deutsch E; Barnathan E; Laskey WK
    Am J Cardiol; 1990 Jun; 65(22):1425-9. PubMed ID: 2353646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina.
    Borries M; Heins M; Fischer Y; Stiegler H; Peters A; Reinauer H; Schoebel FC; Strauer BE; Leschke M
    J Am Coll Cardiol; 1999 Aug; 34(2):486-93. PubMed ID: 10440163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty.
    van den Bos AA; Deckers JW; Heyndrickx GR; Laarman GJ; Suryapranata H; Zijlstra F; Close P; Rijnierse JJ; Buller HR; Serruys PW
    Circulation; 1993 Nov; 88(5 Pt 1):2058-66. PubMed ID: 8222099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina.
    Rupprecht HJ; Terres W; Ozbek C; Luz M; Jessel A; Hafner G; vom Dahl J; Kromer EP; Prellwitz W; Meyer J
    J Am Coll Cardiol; 1995 Dec; 26(7):1637-42. PubMed ID: 7594097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of prolonged intravenous heparin in unstable angina patients prior to coronary angioplasty.
    Gangasani SR; O'Neill WW; Grines CL
    J Interv Cardiol; 2001 Aug; 14(4):423-8. PubMed ID: 12053496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators.
    Serruys PW; Herrman JP; Simon R; Rutsch W; Bode C; Laarman GJ; van Dijk R; van den Bos AA; Umans VA; Fox KA
    N Engl J Med; 1995 Sep; 333(12):757-63. PubMed ID: 7643882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty.
    Wilson JM; Dougherty KG; Ellis KO; Ferguson JJ
    Cathet Cardiovasc Diagn; 1995 Jan; 34(1):1-5. PubMed ID: 7728844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty.
    Doucet S; Malekianpour M; Théroux P; Bilodeau L; Côté G; de Guise P; Dupuis J; Joyal M; Gosselin G; Tanguay JF; Juneau M; Harel F; Nattel S; Tardif JC; Lespérance J
    Circulation; 2000 Mar; 101(9):955-61. PubMed ID: 10704160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying patients at high risk for restenosis after percutaneous transluminal coronary angioplasty for unstable angina pectoris.
    Halon DA; Merdler A; Shefer A; Flugelman MY; Lewis BS
    Am J Cardiol; 1989 Aug; 64(5):289-93. PubMed ID: 2526992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
    Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia E; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R; Karsch KR
    Z Kardiol; 1997 Aug; 86(8):581-91. PubMed ID: 9417748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive clinical pattern of angina at restenosis following coronary angioplasty in unstable angina.
    Foley JB; Chisholm RJ; Common AA; Langer A; Armstrong PW
    Am Heart J; 1992 Nov; 124(5):1174-80. PubMed ID: 1442483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.